Immune system response to Menveo and Twinrix vaccine antigens

The immune system response to Menveo and Twinrix vaccine antigens represents the coordinated activation of the host's adaptive immune system following exposure to specific viral and bacterial components. Menveo is a quadrivalent meningococcal conjugate vaccine that targets Neisseria meningitidis serogroups A, C, Y, and W-135 by conjugating polysaccharides to a CRM197 carrier protein to stimulate T-cell-dependent B-cell responses (FDA, 2020). Twinrix is a combination vaccine containing inactivated Hepatitis A virus and recombinant Hepatitis B surface antigen (HBsAg), which induces the production of neutralizing antibodies against both pathogens (GSK, 2023). The interaction involves antigen-presenting cells (APCs) processing these antigens and presenting them to T and B lymphocytes, leading to the secretion of protective antibodies and the formation of memory cells (CDC, 2021). This response is not a single molecular target but a systemic physiological process used to prevent infectious diseases. Efficacy is typically monitored through biomarkers such as serum bactericidal antibody (hSBA) titers and anti-HBs/anti-HAV antibody levels (WHO, 2022).

Other names

Immune response to MenveoImmune response to TwinrixVaccine-induced immunityMeningococcal and Hepatitis A/B vaccine response

Induction of active immunity through the presentation of bacterial and viral antigens to the host immune system, leading to the production of neutralizing antibodies and immunological memory.